In this independent research project, drug innovations, which include, in particular, high-priced special preparations for the treatment of e.g. MS, rheumatoid arthritis or oncological diseases, are analyzed regarding care relevance, patient acceptance, and risk-benefit ratio. The assessment of drug innovations, approved three years earlier for the German drug market is achieved by comparing reviews of these drugs in standard publications and the evaluation of routine data. The aim of the project is to provide a pharmacological and therapeutic evaluation, to be used by physicians as well as the committees of the GKV (KVen, G-BA, patient organizations) and other stakeholders in the system. The reports are published annually since 2013.